GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (XPAR:MEDCL) » Definitions » EBITDA Margin %

Medincell (XPAR:MEDCL) EBITDA Margin % : -630.76% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Medincell EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medincell's EBITDA for the six months ended in Mar. 2024 was €-13.72 Mil. Medincell's Revenue for the six months ended in Mar. 2024 was €2.18 Mil. Therefore, Medincell's EBITDA margin for the quarter that ended in Mar. 2024 was -630.76%.


Medincell EBITDA Margin % Historical Data

The historical data trend for Medincell's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medincell EBITDA Margin % Chart

Medincell Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only -633.70 -187.88 -524.35 -265.62 -225.12

Medincell Semi-Annual Data
Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -183.82 -391.47 -70.08 -630.76 -87.34

Competitive Comparison of Medincell's EBITDA Margin %

For the Biotechnology subindustry, Medincell's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medincell's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medincell's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Medincell's EBITDA Margin % falls into.



Medincell EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Medincell's EBITDA Margin % for the fiscal year that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2024 )/Revenue (A: Mar. 2024 )
=-20.333/9.032
=-225.12 %

Medincell's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-13.719/2.175
=-630.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medincell  (XPAR:MEDCL) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Medincell EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Medincell's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Medincell Business Description

Traded in Other Exchanges
Address
3 rue des Freres Lumiere, Jacou, FRA, 34830
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Medincell Headlines

No Headlines